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We appreciate van Beek and Chronister’s concerns regarding the funding of harm 
reduction interventions in an environment of diminishing resources (1), however we 
disagree with their conclusion and support the international guidelines for equitable 
and non-discriminatory NSP provision for all people who inject drugs. van Beek and 
Chronister outline the response of the Kirketon Road Centre (KRC),  an established 
primary health care facility in Sydney, New South Wales (NSW), to a potential “public 
policy dilemma” resulting from an increase in the injection of drugs with the primary 
purpose of enhancing image and/or performance in Australia (1). Using data from 
surveys of 102 men injecting image and performance  enhancing drugs (IPEDs) 
attending the KRC Needle and Syringe Program (NSP), they assessed the risk of 
blood-borne viral (BBV) infections in this group to be lower than among people who 
inject  drugs primarily for their psychoactive effects. The KRC subsequently 
implemented a policy decision to limit the availability of injecting equipment from their 
NSP to people who inject IPEDs. The authors also encouraged other NSP services to 
undertake local assessments.
“Cost and capacity” were identified as the main rationale for initiating this restrictive 
policy. IPED injectors comprised a minority of KRC NSP attendees (6%), but were 
receiving 15% of the injecting equipment distributed. A number of factors likely 
contribute to this disparity. Firstly, over two-fifths (44%) of the KRC IPEDs population 
sampled reported collecting equipment for others. Secondly, IPEDs users typically 
procure injecting equipment at the beginning of cycle of multiple drugs requiring both 
intramuscular and subcutaneous administration; potentially creating an impression 
that unreasonably large quantities of injecting equipment are procured. Thirdly, in 
Australia steroid injecting equipment (detached syringe plus injection and drawing up 
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needle) cost less per unit than the combined 1ml needle and syringe; thus 15% of 
injecting equipment does not necessarily equate to 15% of expenditure. In 
Queensland, where a similar increase in people who inject IPEDs was observed over 
the last 5 years (2) and NSP access is unrestricted, the state-wide expenditure on 
injecting equipment for IPED injectors attending NSPs in the 2013/14 financial year 
was approximately AUD$50,000 (R Kemp 2015, pers. comm., 26 October). Assuming 
similar expenditure on IPED injecting equipment in NSW, this represents <1% of the 
annual NSW NSP budget (3) and is relatively inexpensive compared to the cost of 
treating BBV infections (4). Nevertheless, given the 25% reduction in NSP spending 
nationally between 2002-03 (AUD$36.8M) and 2009-10 (AUD$28.75M) (5), we agree 
with van Beek and Chronister that Australian NSP budgets are currently stretched and 
resources provision for NSPs is an issue in other countries.
The primary aim of the NSP is to prevent BBV transmission by providing sterile 
injecting equipment and information on safer injection practices. The results of the 
KRC study indicate that receptive sharing of needles and syringes is low among IPED 
injectors sampled, indicating that they have been successful in minimising injection-
related risk in this population. This success should be applauded. Of concern is the 
high proportion of gay and bisexual men in the KRC study (42%), including four who 
self-reported that they were living with HIV infection. Although none of the KRC 
respondents self-reported hepatitis C virus (HCV) infection, only one third reported
diagnostic screening for HCV in the previous year. Previous Australian research 
identified HCV antibody prevalence of 10% among people who inject steroids (6), 
significantly higher than observed in the general community (7). Sero-prevalence of 
BBVs among IPED injectors in Australia is likely to be comparable to that in United 
Kingdom (UK), with an estimated 1% living with HIV infection, 8% exposed to hepatitis 
Page 4 of 7
Ac
ce
pte
d M
an
us
cri
pt
4
B and 5% to HCV (8), despite relatively short histories of injection. In the UK, the 
National Institute for Health and Care Excellence (NICE) guidelines specifically 
recommend NSP provision to people who inject IPEDs (9). In Australia, the Fourth 
National Hepatitis C Strategy 2014-2017 acknowledges that the drug of choice is 
changing among people who inject drugs (PWID), and states that the injection of 
methamphetamines and performance and image-enhancing drugs is creating new 
groups at risk of hepatitis C, and thus new target groups (10). 
WHO/UNAIDS/UNODC Technical Guide for national HIV prevention, treatment and 
care, advocates universal access among PWID and recommend that services 
(including NSP) should be equitable, non-discriminatory (without exclusion criteria) 
and that supply should be determined by need and not limited by cost or other 
considerations (11). This Technical Guide also states that service access should not 
be restricted by sociodemographic or other criteria, including age, gender, sexual 
behaviour, employment status or substance use status.
As in the UK (12), a high proportion of people who inject IPEDs attending Australian 
NSPs obtain injecting equipment for others, sometimes for many people. This 
suggests that, rather than limit NSP service delivery, greater efforts are required to 
engage with IPEDs injectors who are not currently engaged with harm reduction 
services and may be at greater risk. Harms associated with injection of PIEDs extend 
beyond the transmission of BBVs through injection. In a previous Australian study, 
41% of men who injected steroids reported an injection-related health problem in the 
previous month and 6% reported ever experiencing an injection site abscess (13). A 
recent UK study also identified high prevalence of injection site infections and injuries 
in this population, with over a third reporting redness, swelling or tenderness in the 
previous year and 6-8% ever experiencing an abscess or open wound (14). As in the 
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KRC study, Larance and colleagues (2008) also documented low prevalence of 
receptive needle and syringe sharing (5%), however injection from a shared vial or 
bladder was much more common (29%). Further, high levels of both current 
psychoactive drug use (8, 15) and transitions between IPEDs and psychoactive drug 
have been documented (16). Finally, a screening process to identify ‘need’ of specific 
groups of people who inject drugs, in which those injecting IPEDs are deemed to be at 
negligible risk of BBV transmission, may result in increased complacency and have a 
negative impact on risk behaviour with consequent increases in BBV transmission. 
Australian NSPs have historically been guided by the principles of equity and non-
discrimination in keeping with the universal access advocated in the 
WHO/UNAIDS/UNODC Technical Guide. The provision of NSP access to people who 
inject IPEDs in Australia and elsewhere should be not a public policy dilemma, as all 
forms of injecting drug use have the potential to increase the risk of transmission of 
BBVs and cause other harms.
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